Literature DB >> 12359648

DNA sequence variants in epithelium-specific ETS-2 and ETS-3 are not associated with asthma.

Rebecca M Baron1, Lyle J Palmer, Kelan Tantisira, Stacey Gabriel, Larry A Sonna, Louis Le, Arlene Hallock, Towia A Libermann, Jeffrey M Drazen, Scott T Weiss, Eric S Silverman.   

Abstract

Epithelium-specific ETS-2 and ETS-3 are transcription factors that have been proposed as asthma candidate genes. To investigate the association of sequence variants in these genes with asthma, we conducted a case-control association analysis in a sample of 311 white subjects with asthma and 177 white subjects without asthma. Common polymorphisms in these genes were detected by sequencing DNA from 32 cell lines obtained from Coriel (Camden, NJ). Seven noncoding or synonymous single-nucleotide polymorphisms were detected: three in epithelium-specific ETS-2 and four in epithelium-specific ETS-3. Subjects were genotyped at all loci by mass spectroscopy. To ensure the suitability of our control subjects, we also genotyped subjects at 49 unlinked polymorphisms evenly distributed throughout the autosomes and found no evidence of population stratification. Logistic regression adjusted for age and sex suggested a weak association of one epithelium-specific ETS-2 polymorphism with asthma diagnosis (odds ratio = 1.89, 95% confidence interval = 1.13-3.18, p = 0.02). Total serum immunoglobulin E and FEV1 predicted levels were not associated with any of the polymorphisms. Extended haplotyping indicated linkage disequilibrium in these genes; however, no association or epistatic interaction was found. This study suggests that epithelium-specific ETS-2 and ETS-3 genes are unlikely to contain polymorphic loci that have a major impact on asthma susceptibility in our population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359648     DOI: 10.1164/rccm.200201-048OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  5 in total

1.  Polygenic heritability estimates in pharmacogenetics: focus on asthma and related phenotypes.

Authors:  Michael J McGeachie; Eli A Stahl; Blanca E Himes; Sarah A Pendergrass; John J Lima; Charles G Irvin; Stephen P Peters; Marylyn D Ritchie; Robert M Plenge; Kelan G Tantisira
Journal:  Pharmacogenet Genomics       Date:  2013-06       Impact factor: 2.089

2.  ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts.

Authors:  Augusto A Litonjua; Jessica Lasky-Su; Kady Schneiter; Kelan G Tantisira; Ross Lazarus; Barbara Klanderman; John J Lima; Charles G Irvin; Stephen P Peters; John P Hanrahan; Stephen B Liggett; Gregory A Hawkins; Deborah A Meyers; Eugene R Bleecker; Christoph Lange; Scott T Weiss
Journal:  Am J Respir Crit Care Med       Date:  2008-07-10       Impact factor: 21.405

3.  A graphical assessment of p-values from sliding window haplotype tests of association to identify asthma susceptibility loci on chromosome 11q.

Authors:  Rasika A Mathias; Peisong Gao; Janet L Goldstein; Alexander F Wilson; Elizabeth W Pugh; Paulette Furbert-Harris; Georgia M Dunston; Floyd J Malveaux; Alkis Togias; Kathleen C Barnes; Terri H Beaty; Shau-Ku Huang
Journal:  BMC Genet       Date:  2006-06-14       Impact factor: 2.797

Review 4.  Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies.

Authors:  Miles D Thompson; Valerie Capra; Mark T Clunes; G E Rovati; Jana Stankova; Mary C Maj; David L Duffy
Journal:  Front Pharmacol       Date:  2016-12-01       Impact factor: 5.810

5.  A genome-wide association study of bronchodilator response in asthmatics.

Authors:  Q L Duan; J Lasky-Su; B E Himes; W Qiu; A A Litonjua; A Damask; R Lazarus; B Klanderman; C G Irvin; S P Peters; J P Hanrahan; J J Lima; F D Martinez; D Mauger; V M Chinchilli; M Soto-Quiros; L Avila; J C Celedón; C Lange; S T Weiss; K G Tantisira
Journal:  Pharmacogenomics J       Date:  2013-03-19       Impact factor: 3.550

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.